| P/E (FY) | — | Sales (TTM) | $57.0M |
| Earnings (TTM) | -$107.2M | ROE | −37.23% |
| Net Margin | −162.85% | ROIC | −48.32% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 35.89% |
Tango Therapeutics is a precision oncology company focused on discovering and developing drugs for defined patient populations with unmet medical need. It develops PRMT5 inhibitors including TNG462, in Phase 1/2 trials for pancreatic and lung cancer, and TNG456, a brain-penetrant inhibitor for glioblastoma. The company is also developing TNG260, a co-repressor inhibitor intended to reverse immune evasion linked to STK11 loss-of-function mutations in lung cancer.
| Market Cap | $3.85B | Trading Days | 1239 |
| 52W High | 34.39 |
| 52W Low | 5.77 |
| % Off High | −22.51% |
| YTD | 200.79% | 1Y | 299.55% |
| 3Y | 773.77% | Since incept. (ann.) | 22.97% |
Collaboration Revenue 100%
| Ann. Volatility (1Y) | 101.20% | Ann. Volatility (3Y) | 116.08% |
| Sharpe (1Y) | 1.86 | Sharpe (3Y) | 1.14 |
| Max Drawdown (1Y) | −29.24% | Max Drawdown (3Y) | −91.46% |
| Beta (3Y, vs SPY) | −0.27 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CPRX | CATALYST PHARMACEUTICALS, INC. | $3.85B | 18.7 |
| VKTX | Viking Therapeutics, Inc. | $3.93B | — |
| DYN | Dyne Therapeutics, Inc. | $3.70B | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.55B | — |
| OGN | Organon & Co. | $3.55B | 18.8 |
| EWTX | Edgewise Therapeutics, Inc. | $4.34B | — |
| RCUS | Arcus Biosciences, Inc. | $3.40B | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $4.45B | 11.3 |
| ELVN | Enliven Therapeutics, Inc. | $3.27B | — |
| MANE | Veradermics, Inc | $4.66B | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.18B |
| INDV | Indivior Pharmaceuticals, Inc. | $5.00B | 25.0 |
